TCT联合高危HPV—DNA定量检测在宫颈疾病筛查中的价值

目的通过液基细胞学（TCT）联合高危型（8个型）人乳头瘤病毒DNA（HR—HPV—DNA）定量检测，探讨其在宫颈疾病筛查中的价值。方法对怀疑有宫颈病变的患者进行（TCT）和HR—HPV—DNA（16，18，31，33，45，52，56，58型）实时荧光定量检测，并将两者结果和病理活检进行对照分析。结果TCT检测与HR—HPV—DNA检测特异性比较有显著差别（P〈0．01），HR—HPV—DNA检测诊断敏感度高（92％），但特异性低（75％）；TCT检查特异性高（97％），敏感性低（83％）；TCT与联合筛查检出率高达100％，两组比较有明显差别（P〈0．01）。结论TCT联合HR—HPV—DNA进行宫颈疾病的筛查，能明显提高检出率和筛查效率，在宫颈癌高危人群中进行大规模的初筛更具价值，适合在条件允许的地方进行开展。

The Value of TCT combined with high - risk HPV - DNA quantitative detection in screening of cervical diseases

Objective To explore the value of TCT in combination with quantitative detection of high - risk type human papillomavirus （HPV） DNA （8 types） in screening cervical diseases. Methods Suspected patients with cervi- cal lesion were examined with TCT and the high risk HPV -DNA （type 16,18,31,33,45,52,56, and 58） by using real -time fluorescence quantitative detection, and both results and pathological biopsy were analyzed comparative- ly. Results There was significant difference （ P 〈 0.01 ） between TCT detection and high risk HPV - DNA detection in the specificity. The sensitivity of high risk HPV - DNA diagnosis is higher （ 92% ）, but specificity is lower （75%） ; whereas the specificity of TCT is higher （97%）, but sensitivity is lower （83%） ; TCT combined with high risk HPV -DNA detection could increase the rate of detecting cervical diseases to 100% ,and the comparison of two groups was significantly different （P 〈 0.01 ）. Conclusion TCT combined with quantitative detection of high risk HPV- DNA for screening cervical diseases can significantly improve detection rate and screening efficiency, which is more valuable to carry out on a large scale screening for cervical cancer in high - risk populations at early stage and suitable in places where conditions permit.